Tag Archives: labeling

August 2011 FDA Guidances

Here’s a (very lengthy) list of the guidances released by FDA in August 2011, compiled by Cato Research Regulatory Scientist Cathy Anderson. Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring (Draft) Postmarket Surveillance Under Section 522 of the … Continue reading

Posted in Clinical Trials, FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , , , , , | 1 Comment

New Guidances from FDA – May 2011

Here’s a list of the guidances released by FDA in May 2011 (along with a couple that were released inthe first week of June), compiled by Cato Research Regulatory Scientist Cathy Anderson. Commercially Distributed In Vitro Diagnostic Products Labeled for … Continue reading

Posted in FDA | Tagged , , , , , , , , | Comments Off

New FDA Guidances – March 2011

Each month, Cato Research Regulatory Scientist Cathy Anderson compiles a list of the notable guidance documents released by the FDA.  Here’s a summary of the guidances released in March 2011 (most links go directly to PDF documents). Postmarketing Studies and … Continue reading

Posted in Clinical Trials, FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , | Comments Off

FDA Guidances – December 2010

Each month, Cato Research Regulatory Scientist Cathy Anderson compiles a list of the notable guidance documents released by the FDA.  Here’s a summary of the guidances released in December 2010, including a few from the first week of January 2011 … Continue reading

Posted in Clinical Trials, FDA, Industry News, Regulatory Strategy | Tagged , , , , , | Comments Off

September 2010 FDA Guidances

Image via Wikipedia Each month, Cato Research Regulatory Scientist Cathy Anderson compiles a list of the notable guidance documents released by the FDA.  Here’s a summary of the guidances released in September 2010 (links go directly to PDF documents). Special … Continue reading

Posted in FDA, Industry News | Tagged , , , , , , , | Comments Off